Event ·Multi-source

OpenAI 收购 Orchestra Bio，用 AI 智能体协调药物研发流程

OpenAI 收购了 Orchestra Bio，这家公司的 AI 智能体负责追踪药物项目的跨部门协调工作。此前 OpenAI 已有 Rosalind 产品线：GPT-Rosalind 负责生物与化学推理，Rosalind Workbench 把模型接入实验室工具与数据。Orchestra 补的是另一块短板——当某批生产失败时，其智能体会梳理哪些试验受影响并给出应对方案。Anthropic 曾在 4 月以约 4 亿美元股票收购 Coefficient Bio，两大实验室都在收购专业生物医药团队。新药从靶点到美国批准平均仍需 10-15 年。

Current read

OpenAI 和 Anthropic 都开始买生物医药团队了，这次收的 Orchestra 专管药物项目里的跨部门协调，跟 Rosalind 的科研推理正好互补。

11 sources68° AI heatLast updated 2026/10/20 18:58:27

Evidence

11 sources

Primary sourcerohanpaul_ai

2026/10/20 18:58:27View source

Related source 1kimmonismus

2026/10/20 21:21:35View source

Related source 2IT之家

2026/10/20 22:51:11View source

Related source 3TestingCatalog

2026/10/20 18:21:43View source

Related source 4techcrunch

2026/10/20 20:35:10View source

Related source 5OpenAI Blog

2026/10/20 00:00:00View source

Related source 6Decoder

2026/10/21 08:32:54View source

Related source 7Mark Chen (OpenAI 研究)

2026/10/20 19:33:08View source

Related source 8Tech in Asia

2026/10/21 06:21:20View source

Related source 9a16z

2026/10/19 14:37:04View source

Related source 10Latent.Space

2026/10/19 15:03:00View source

Conflict check

Dedup data only shows that these sources discuss the same event, not that they agree. There is no structured supporting or refuting evidence yet, so no conflict is inferred automatically.

Open the story